Cypherpunk Technologies (NASDAQ:CYPH) Posts Earnings Results, Misses Expectations By $0.42 EPS

Cypherpunk Technologies (NASDAQ:CYPH) released its quarterly earnings data on Thursday. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.42), FiscalAI reports.

Cypherpunk Technologies Price Performance

CYPH stock traded up $0.16 during midday trading on Thursday, hitting $1.20. 5,738,842 shares of the stock traded hands, compared to its average volume of 3,743,656. The firm has a market cap of $117.22 million, a P/E ratio of 17.14 and a beta of -0.09. The stock’s fifty day simple moving average is $0.83 and its 200-day simple moving average is $0.99. Cypherpunk Technologies has a 1-year low of $0.23 and a 1-year high of $3.70.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Cypherpunk Technologies from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Cypherpunk Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CYPH. Acadian Asset Management LLC grew its position in Cypherpunk Technologies by 470.4% during the first quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock valued at $389,000 after buying an additional 1,056,047 shares during the period. HighTower Advisors LLC acquired a new stake in Cypherpunk Technologies during the fourth quarter valued at $59,000. Geode Capital Management LLC acquired a new stake in Cypherpunk Technologies during the fourth quarter valued at $615,000. LPL Financial LLC acquired a new stake in Cypherpunk Technologies during the fourth quarter valued at $38,000. Finally, State Street Corp acquired a new stake in Cypherpunk Technologies during the fourth quarter valued at $163,000. Institutional investors and hedge funds own 30.46% of the company’s stock.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.